Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing

被引:25
|
作者
Mannis, Gabriel N. [1 ]
Fehniger, Julia E. [2 ]
Creasman, Jennifer S. [3 ,4 ]
Jacoby, Vanessa L. [3 ]
Beattie, Mary S. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Div Hematol Oncol, Dept Internal Med, San Francisco, CA 94117 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Canc Risk Program, San Francisco, CA 94117 USA
[3] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94117 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA
关键词
BREAST-CANCER; CLINICAL CHARACTERISTICS; MUTATION CARRIERS; REDUCTION; TIME; METAANALYSIS; ASSOCIATION; PREDICTORS; ULTRASOUND; EFFICACY;
D O I
10.1001/2013.jamainternmed.962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non-BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions. Methods: A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125). Results: Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Over-all, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing. Conclusions: Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non-BRCA carriers despite insufficient data to determine the effectiveness of these interventions. JAMA Intern Med. 2013; 173(2):96-103. Published online December 17, 2012. doi:10.1001/2013.jamainternmed.962
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [1] Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
    Shu, Catherine A.
    Pike, Malcolm C.
    Jotwani, Anjali R.
    Friebel, Tara M.
    Soslow, Robert A.
    Levine, Douglas A.
    Nathanson, Katherine L.
    Konner, Jason A.
    Arnold, Angela G.
    Bogomolniy, Faina
    Dao, Fanny
    Olvera, Narciso
    Bancroft, Elizabeth K.
    Goldfrank, Deborah J.
    Stadler, Zsofia K.
    Robson, Mark E.
    Brown, Carol L.
    Leitao, Mario M., Jr.
    Abu-Rustum, Nadeem R.
    Aghajanian, Carol A.
    Blum, Joanne L.
    Neuhausen, Susan L.
    Garber, Judy E.
    Daly, Mary B.
    Isaacs, Claudine
    Eeles, Rosalind A.
    Ganz, Patricia A.
    Barakat, Richard R.
    Offit, Kenneth
    Domchek, Susan M.
    Rebbeck, Timothy R.
    Kauff, Noah D.
    JAMA ONCOLOGY, 2016, 2 (11) : 1434 - 1440
  • [2] Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy
    Chan, Jessica L.
    Senapati, Suneeta
    Johnson, Lauren N. C.
    DiGiovanni, Laura
    Voong, Chan
    Butts, Samantha F.
    Domchek, Susan M.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (02): : 132 - 139
  • [3] Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
    Johansen, Nora
    Liavaag, Astrid H.
    Iversen, Ole-Erik
    Dorum, Anne
    Braaten, Tonje
    Michelsen, Trond M.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2017, 96 (05) : 547 - 555
  • [4] Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer
    Meiser, Bettina
    Price, Melanie A.
    Butow, Phyllis N.
    Karatas, Janan
    Wilson, Judy
    Heiniger, Louise
    Baylock, Brandi
    Charles, Margaret
    McLachlan, Sue-Anne
    Phillips, Kelly-Anne
    FAMILIAL CANCER, 2013, 12 (01) : 101 - 109
  • [5] The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy
    van der Aa, Jessica E.
    Hoogendam, Jacob P.
    Butter, Els S. F.
    Ausems, Margreet G. E. M.
    Verheijen, Rene H. M.
    Zweemer, Ronald P.
    FAMILIAL CANCER, 2015, 14 (04) : 539 - 544
  • [6] Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer
    Nomura, Hidetaka
    Ikki, Ai
    Fusegi, Atsushi
    Omi, Makiko
    Aoki, Yoichi
    Netsu, Sachiho
    Tanigawa, Terumi
    Matoda, Maki
    Okamoto, Sanshiro
    Omatsu, Kohei
    Nakajima, Takeshi
    Ueki, Arisa
    Tonooka, Akiko
    Kanao, Hiroyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2331 - 2337
  • [7] Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status
    Manchanda, R.
    Abdelraheim, A.
    Johnson, M.
    Rosenthal, A. N.
    Benjamin, E.
    Brunell, C.
    Burnell, M.
    Side, L.
    Gessler, S.
    Saridogan, E.
    Oram, D.
    Jacobs, I.
    Menon, U.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2011, 118 (07) : 814 - 824
  • [8] Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer
    Fakkert, Ingrid E.
    Abma, Elske Marije
    Westrik, Iris G.
    Lefrandt, Joop D.
    Wolffenbuttel, Bruce H. R.
    Oosterwijk, Jan C.
    Slart, Riemer H. J. A.
    van der Veer, Eveline
    de Bock, Geertruida H.
    Mourits, Marian J. E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 400 - 408
  • [9] Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants
    Choi, Yun-Hee
    Terry, Mary Beth
    Daly, Mary B.
    MacInnis, Robert J.
    Hopper, John L.
    Colonna, Sarah
    Buys, Saundra S.
    Andrulis, Irene L.
    John, Esther M.
    Kurian, Allison W.
    Briollais, Laurent
    JAMA ONCOLOGY, 2021, 7 (04) : 585 - 592
  • [10] Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations
    Smith, Maria J.
    Gerber, Deanna
    Olsen, Anne
    Khouri, Olivia R.
    Wang, Yuyan
    Liu, Mengling
    Smith, Julia
    Pothuri, Bhavana
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (05)